FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia by Schnittger, Susanne et al.
Review
Acta Haematol 2004;112:68–78
DOI: 10.1159/000077561
FLT3 Length Mutations as Marker for
Follow-Up Studies in Acute Myeloid
Leukaemia 
Susanne Schnittger Claudia Schoch Wolfgang Kern Wolfgang Hiddemann
Torsten Haferlach
Laboratory for Leukaemia Diagnostics, Department of Internal Medicine III, Ludwig Maximilians University of
Munich, University Hospital Grosshadern, Munich, Germany
Dr. rer. nat. Susanne Schnittger, Laboratory for Leukaemia Diagnostics
Department of Internal Medicine III, University Hospital Grosshadern
Ludwig Maximilians University, Marchioninistrasse 15
DE–81377 München (Germany), Tel. +49 89 7095 4970, Fax +49 89 7095 4971
E-Mail susanne.schnittger@med3.med.uni-muenchen.de
ABC
Fax + 41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
© 2004 S. Karger AG, Basel
0001–5792/04/1122–0068$21.00/0
Accessible online at:
www.karger.com/aha
Key Words
FLT3-LM W Minimal residual disease W AML W FLT3-ITD W
Follow-up studies
Abstract
Length mutations within the FLT3 gene (FLT3-LM) can be
found in 23% of acute myeloid leukaemia (AML) and thus
are the most frequent mutations in AML. FLT3-LM are
highly correlated with AML with normal karyotype and
other cytogenetic aberrations of the prognostically inter-
mediate group. This group is supposed to be a mixed
group of AML with differences in the underlying patho-
genesis. For more individualized treatment options it
would be helpful to better characterize this large AML
group not only by molecular mutations but also use
these markers for the definition of minimal residual dis-
ease (MRD). However, so far the cytogenetically interme-
diate AML has been lacking suitable markers for PCR-
based MRD detection like the fusion genes in the prog-
nostically favourable subgroups. The suitability of the
FLT3-LM as a target for PCR-based MRD was discussed
controversially as it seemed to be a rather unstable
marker. Thus, we aimed at the evaluation of FLT3-LM as
a marker for residual disease in a large cohort of AML.
Paired samples of 97 patients with AML at diagnosis and
at relapse were analyzed. It could be shown that in only
four cases a loss of the length mutation was detected.
This is in the range of other well-characterized AML
relapsing with a different geno- and/or phenotype. In
contrast, a change in the ratio of the mutated allele in
comparison to the wild-type allele was frequently ob-
served. In detail, the FLT3-LM showed a tendency to
accumulate during disease progression and was found
more frequently at relapse than at diagnosis. In addition,
45 patients were analyzed at different time points during
and after therapy. Using conventional PCR it clearly
could be shown that for most of the patients positive at
presentation FLT3-LM is a reliable PCR marker for moni-
toring treatment response. Even an early detection of
relapse was possible in some cases.
Copyright © 2004 S. Karger AG, Basel
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Introduction
FLT3 is a member of fms-like receptor tyrosine kinases
and is expressed in early haematopoietic stem cells [1, 2].
The gene coding for this receptor is targeted by mutations
in the juxtamembrane domain in 20–23% of all unselect-
ed acute myeloid leukaemias (AML) [3–8]. In addition,
point mutations in the activation domain have been
described in an additional 6–7% of AML [9–11]. Thus,
FLT3 is the gene most commonly targeted by mutations
in AML. The mutations in exon 14 and/or exon 15, the
part of the gene that is coding for the juxtamembrane
domain, have been described to be internal tandem dupli-
cations (ITD) resulting in the term FLT3-ITD. However,
as we have found that not all of these mutations are sim-
ple ITDs but about 30% have insertions of extranucleo-
tides between the duplicated stretches and some cases are
even more complicated, we will refer to this mutations as
FLT3 length mutations (FLT3-LM) [8]. The elongation of
the juxtamembrane domain results in a conformation
change that leads to autoactivation of the receptor
through a constitutive phosphorylation [12] and can in-
duce IL-3-independent growth in model systems [13, 14].
The FLT3-LM has been shown to be strongly correlated
with AML and myelodysplastic syndromes of the RAEB
and RAEBt subtypes [8, 15]. In many different study
groups the FLT3-LM has been shown to be strongly corre-
lated with the prognostically intermediate karyotype
group. This large group of AML is supposed to be a pool of
insufficiently characterized AML with different molecu-
lar mutations. Now it is becoming clear that the FLT3-
LM defines a prognostically worse subset within this
group [3, 5–8, 16, 17]. Today the karyotype of the leu-
kemic cells is considered the most important parameter
indicating the prognosis in patients with AML [18, 19].
Although further pretherapeutically defined prognostic
parameters have been identified such as age of the patient
and AML occurring as a secondary disease the prognosis
of patients within the respective subgroups defined by
these parameters is still heterogeneous. As a consequence,
the implementation of therapy-dependent parameters
into stratification systems has been approached. Along
this line, the degree of reduction of the leukemic cell mass
following the first course of induction therapy as well as
the time to achieve complete remission have been demon-
strated to independently impact the prognosis [20–22].
These studies thus have proved the concept of prognosti-
cation based on therapy-dependent factors.
The most prominent therapy-related factor is the level
of minimal residual disease (MRD). Beside the conven-
tional control of therapy response by cytomorphology,
assessment of MRD by flow cytometry is of growing
importance [23]. However, polymerase chain reaction
(PCR)-based methods are still the most sensitive ones for
the detection of residual leukaemic cells. The application
of PCR to quantify MRD so far was based on the presence
of fusion genes or their respective fusion transcripts,
which occur exclusively in the respective subentities of
AML but not in normal bone marrow. In patients with
AML the detection of MRD by quantitative PCR has
been shown to be feasible and prognostically relevant [24–
32]. However, in AML with normal karyotype or other
prognostically intermediate aberrations like trisomies 8 or
11 and del(9q) PCR was not applicable due to the lack of a
target suitable for PCR. The portion of cases assessable
may now be extended by the inclusion of cases with
FLT3-LM.
To analyze whether FLT3-LM is a valuable marker for
follow-up controls two different analyses were performed:
(1) the stability was assessed by paired analysis of samples
from diagnosis and relapse and (2) FLT3 status from sam-
ples during and after therapy was compared to the status
of remission, fluorescence in situ hybridization (FISH)
and cytogenetics.
Patients, Materials and Methods
Patient Samples
Bone marrow or peripheral blood samples were sent by overnight
service to our lab. All were diagnosed as having AML according to
standard French-American-British (FAB) criteria [33–38] and were
referred between July 1997 and December 2002 for cytomorphologi-
cal, cytogenetic, molecular genetic and multiparameter flow cytome-
try analysis.
Cytogenetic and FISH Analysis 
Cytogenetic G-banding analysis was performed with standard
methods [39]. The definition of a cytogenetic clone and descriptions
of karyotypes followed the International System for Human Cytoge-
netic Nomenclature [40].
For FISH the commercially available probes CEP#8SG,
LSID7S486/CEP7, LSIPMLRARA, LSICBFB, and LSIAML1/ETO
were used according to the manufacturer’s instructions (Vysis, Ber-
gisch Gladbach, Germany).
Sample Preparation
Mononucleated bone marrow cells were obtained by Ficoll-Hy-
paque density gradient centrifugation. Total RNA was extracted
from 107 cells with RNeasy (Qiagen, Hilden, Germany) (1997–2000)
or mRNA with the MagnaPureLC mRNA Kit I (Roche Diagnostics,
Mannheim, Germany) (since January 2001). The cDNA synthesis of
1–2 Ìg total RNA or mRNA from an equivalent of 107 cells was per-
formed using 300 U Superscript II (GibcoBRL/Invitrogen, Karls-
ruhe, Germany) and random hexamer primers (Pharmacia, Freiburg,
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Germany). DNA was extracted using a simple salting-out procedure
[41].
PCR at Diagnosis
PCR and semiquantitative estimation of the FLT3-LM status
was performed as has been described [8]. Strict precautions were tak-
en to prevent contamination. Water instead of cDNA was included
as a blank sample in each experiment. Amplification products were
analyzed on 2% agarose gels stained with ethidium bromide.
Sequencing
For direct sequencing of the length mutations the amplified frag-
ments were cut from the agarose gels and isolated with Quiaex II
(Qiagen) following the manufacturer’s instructions. Approximate-
ly 100 ng of purified PCR products were directly sequenced with
3.3 pmol of primers as described above with the Big Dye Terminator
Cycle Sequencing Kit (Applied Biosystems, Weiterstadt, Germany).
After initial denaturation at 95°C for 5 min, 25 cycles at 94°C for
15 s and 60°C for 4 min were performed. Cases with a relatively
small length of the mutations or those with status 1 or 5 mutations
were subcloned using the TOPO II cloning system (Invitrogen, Karls-
ruhe, Germany) prior to sequence analysis. Sequence detection was
performed on an ABI 310 sequence detection system (Applied Bio-
systems).
Efficiencies, Reproducibility and Sensitivities of the PCR Assays
The sensitivity of the PCR assays was assessed by performing
limited dilution series of DNA and cDNA of diagnostic patient sam-
ples with a different status of FLT3-LM into cDNA of samples with-
out FLT3-LM.
Results
Frequency of FLT3-LM at Presentation and in
Relapse
In total 2,338 samples were analyzed, 2,135 were from
newly diagnosed AML and 203 from relapsed AML.
FLT3-LM were found in 461 (21.6%) of the diagnostic
samples at first diagnosis and in 62 (30.5%) of the
relapses. Thus the frequency is higher in relapsed AML
(table 1) (p = 0.005).
Semiquantitative Analysis of the Mutations
Analysis of the amplification fragments on agarose gels
revealed that the band representing the mutation was not
always of the same intensity as the wild-type allele. Thus,
we divided the FLT3-LM into five categories: (1) mutant
fragment less intense than wild-type band (status 1),
(2) mutant fragment with the same intensity as wild-type
band (status 2), (3) mutant fragment more intense than
wild-type band (status 3), (4) only mutant fragment and
loss of wild-type band (status 4), and (5) presence of more
than one mutant fragment (status 5) (fig. 1). Type 1 has to
be interpreted as subclone in an otherwise FLT3-LM-neg-
Table 1. FLT3-LM status according to a semiquantitative estima-
tion in a cohort of 2,135 AML patients at diagnosis and 203 at
relapse
Mutation
status
Diagnoses
(461/2,135; 21.6%), %
Relapse
(62/203; 30.5%), %
1 10 –
2 60 16
3 11 32
4 6 52
5 13 –
ative population, type 2 as an equal amount of wild-type
and mutated allele, type 3 as loss of the wild type in a
subclone, and type 4 as complete loss of the wild type. In
type 5 there were two different FLT3-LM in different
clones.
At diagnosis 70% of the patients with FLT3-LM have
status 1 and 2 mutations, whereas a loss or partial loss of
the wild-type allele was found in only 17%. In contrast, in
relapses status 1 and 5 was never detected and status 2 in
only 16%. Most of the relapsed FLT3-LM-positive cases
had a partial (32%) or complete (52%) loss of the WT-
FLT3.
Use of DNA and cDNA for PCR Diagnostics
The PCR screening for FLT3-LM was done at the
genomic and cDNA level in parallel for most of the cases.
For some cases with limited material the analysis was
restricted to the cDNA level. No major differences con-
cerning the intensities of the mutated allele in comparison
to the wild-type allele were observed, suggesting that there
were no major expression differences between wild-type
and mutated alleles.
At diagnosis it was possible to detect an FLT3 expres-
sion in every sample. In contrast, in follow-up samples of
patients in complete clinical remission, it was not always
possible to obtain an amplification product of FLT3 by
PCR. This is in accordance with previous studies that
have shown FLT3 expression on early haematological and
leukaemic cells but not on differentiated haematological
cells [2]. Thus for follow-up controls DNA is highly rec-
ommended as diagnostic material.
Paired Samples from Diagnosis and Relapse
In total the FLT3 status was assessed in 97 paired sam-
ples at diagnosis and at relapse (table 2). Fifty-one pa-
tients were negative at both time points. Thirty-eight
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Fig. 1. Assessment of the FLT3-LM status
according to mutation/wild-type relation.
Table 2. FLT3-LM in paired presentation
and relapse samples: present study and
review of the literature
Patients FLT3 status at presentation/relapse
–/– –/+ +/– +/+
Nakano et al. [48] 28 16 6 1 5*
Kottaridis et al. [16] 44 20 4 5 15*
Hovland et al. [42] 2 – 1 – 1
Shih et al. [44] 108 83 8 1 16*
Present study 97 51 4 4 38
Total 278 170 (61.2%) 23 (8.3%) 11 (4%) 75 (27%)
cases were positive for an FLT3-LM at both time points.
All 3 cases with a second relapse retained the FLT3-LM at
that time point. A gain of an FLT3-LM was found in 4
cases. A loss of the mutation was detected in only 4 cases
(IDs 2, 41, 42, 43), three of whom had only a status 1
mutation at presentation (table 3), meaning that at diag-
nosis only a subclone of all leukemic cells had the muta-
tion. Of the 4 cases with a gain of the FLT3 mutation, in
two (IDs 44 and 47) also a change of the FAB from M4 to
M2 and M6 to M1, a change of the immunophenotype
and in case 47 also a different karyotype were observed
raising the question of whether these two might be sec-
ondary AML rather than relapsed AML. In addition, in
case 46 the same FAB but a complete change of the karyo-
type was observed.
Focussing on the FLT3 status (relation of the mutated
to the WT-FLT3) in more detail (table 4 and 5) we found
stability of the status in 12 cases (24.5%); however, a pro-
gression from lower to higher status was detected in 30
cases (63%) and a regression to lower status or loss of the
FLT3-LM in only 6 cases (12.2%). Thus the overall main-
tenance of an FLT3-LM in relapse was relatively stable
with (45/49; 91.8%). However the mutation had a tenden-
cy to accumulate during progression of leukaemia.
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Table 3. Paired samples of patients with FLT3-LM at diagnosis and/or relapse (n = 47)
ID FAB FLT3-LM
status
Karyotype ID FAB FLT3-LM
status
Karyotype
1 PD M0 3 46,XX [24]
1 Rel M0 3 46,XX [5]
2 PD M1 2 46,XX [25]
2 Rel M1 – 46,XX 
3 PD M1 2 46,XX [25]
3 Rel M1 3 46,XX [8]
4 PD M1 2 46,XX [25]
4 Rel M1 3 46,X,del(X)(q11),t(7;18)(q22;p11.2)[8]/
46,XX [7]
5 PD M1 4 48,XY,+8,+10 [10]
5 Rel M1 2 46,XY [25]
6 PD M1 4 46,XY [20]
6 Rel M1 4 n.d.
7 PD M1/M2 2 46,XY [6]
7 Rel ? 4 n.d.
8 PD M2/M4 1 46,XX [12]
8 Rel M2 3 n.d.
9 PD M2 4 46,XX [25]
9 Rel M2 4 46,XX [6]
10 PD M2 1 46,XY [25]
10 Rel M2 4 46,XY [21]
11 PD M2 2 46,XY [22]
11 Rel M2. 3 46,XY [25]
12 PD M2 2 46,XY [25]
12 Rel M2 4 49,XY,+8,+13,+19 [20]
13 PD M2 2 46,XX [24]
13 1. Rel M2 2 46,XX,t(1;19;3)(p32;q13?;p21)[25]/
46,XX [2]
13 2. Rel M2 2 46,XX,t(1;19;3)(p32;q13?;p21)[14]/
46,XX [1]
14 PD M4 5 46,XX [25]
14 Rel ? 5 46,XX [25]
15 PD M4 2 46,XX [25]
15 Rel M4 3 46,XX [25]
16 PD M4 3 46,XX [25]
16 Rel M4 3 46,XX [25]
17 PD M4 2 46,XX [25]
17 Rel M4 3 46,XX [15]
18 PD M4/M5 2 46,XY [25]
18 Rel M4/M5 2 48,XY,t(2;3)(q31;p21),+8,+8,t(10;17)
(q22;q22), del(13)(q14q31)[13]/46,XY [12]
19 PD M4 3 46,XX [25]
19 Rel M4Rez 4 46,XX [25]
20 PD M5b 3 46,XX [20]
20 1. Rel M5b 4 46,XX [20]
20 2. Rel M5b 4 46,XX [20]
21 PD M5b 3 46,XX [25]
21 Rel M5bRez 4 46,XX [25]
22 PD M5b 1 46,XX [25]
22 Rel M1 4 46,XX [25]
23 PD AML 2 46,XY [15]
23 1. Rel AML 2 46,XY,t(10;12)(q22;p13)[6]/46,XY [6]
23 2. Rel AML 2 46,XY,t(10;12)(q22;p13)[14]/46,XY [1]
24 PD M2 2 46,XY,t(8;21)(q22;q22) [25]
24 Rel M2 2 46,XY,t(1;5)(q21;q33),t(8;21)(q22;q22)[6]/
46,XY,t(1;5)(q21;q33),t(8;21)(q22;q22),
del(11)(p13) [4]
25 PD M0/M1 2 46,XY,der(5)t(5;11)(q22;?)[9]/46,XY [11]
25 Rel M0 3 46,XY [20]
26 PD M0 2 46,XY,t(11;19)(q13;p13)[17]/46,XY [3]
26 Rel M0 2 46,XY,t(11;19)(q13;p13)[9]/46,XY [1]
27 PD M0
(Chlorom)
2 48,XX,+8,+22[4]/46,XX [20]
27 Rel M0 3 50,XX,+X,+8,+10,+13 [3]
28 PD M2 2 47,XX,del(5)(q15q33)+11 [20]
28 Rel M2 3 47,XX,del(5)(q15q33)+11[9]/
47,idem,del(17)(q23)[9]/
47,idem,add(7)(q3?4)[2]
29 PD M4 2 46,XX,inv(3)(q21q26)[17]/46,XX [8]
29 Rel M4 3 46,XX,inv(3)(q21q26)[7]/46,XX [13]
30 PD tM4 5 46,X,i(X)(q10)[4]
46,XX [19]
30 Rel M1 2 46,XX [20]
31 PD M5a 1 46,XY,del(11)(q13q21) or
del(11)(q21q23)[6]/47,idem,+8[13]/
46,XY [3]
31 Rel M5a 2 46,XY,del(11)(q13q21) or
del(11)(q21q23)[1]/47,idem,+8 [19]
32 PD M5b 2 47,XY,+8[16]/46,XY [4]
32 Rel M5b 2 47,XY,+8 [15]
47,XY,t(1;18)(p22;q23),+8,del(11)
(p11.2p15) [5]
33 PD M1 1 46,XX [25]
33 Rel M1 3 46,XX [15]
34 PD M1 1 46,XX [22]
34 Rel M1 4 46,XX [25]
35 PD M2 2 46,XY,der(7)t(1;7)(q31;q32)[8]/46,XY [8]
35 Rel M2 4 46,XY,t(3;6)(q21;p12),der(7)t(1;7)
(q31;q32),der(10)t(8;10)(q22;q26),t(12;15)
(q13;q22)[13]/46,XY [2]
36 PD M1 2 46,XX [21]
36 Rel M2 4 46,XX [20]
37 PD M5b 2 46,XX [25]
37 Rel M5b 2 46,XX [25]
38 PD M3v 1 46,XY,t(15;17)(q22;q12)[3]46,XY,
der(15)t(15;17)(q22;q12),ider(17)(q10)
t(15;17) (q22;q12) [17]
38 Rel M3v 3 46,XY,t(15;17)(q22;q21)[18]/46,XY [2]
39 PD M5a 1 46,XX [25]
39 Rel M5a 4 46,XX [25]
40 PD M1 1 46,XY [21]
40 Rel M1 4 46,XY [18]
41 PD M2 1 46,XX,t(8;21)(q22;q22)[19]/46,XX [1]
41 Rel M2 0 46,XX,t(8;21)(q22;q22)[11]/46,XX [4]
42 PD sAML 1 47,XY,+8 [15]
42 Rel sAML 0 47,XY,+8[4]/46,XY [16]
43 PD M4eo 1 46,XY,inv(16)(p13q22)[2]/
47,XY,+8,inv(16)(p13q22)[1]49,XY,del(1)
(q21),+8,+13,inv(16)(p13q22),+21 [4]
43 Rel M4eo 0 46,XY,inv(16)(p13q22)
[1]\n47,XY,+8,inv(16)(p13q22) 
44 PD M4 0 46,XX [25]
44 Rel M2 3 46,XX [20]
45 PD M1 0 46,XX [26]
45 Rel M1 1 46,XX [20]
46 PD M1 0 46,XY,del(7)(q21)[5]/46,XY [13]
46 Rel M1 2 47,XY,+13[2]/47,XY,+15[2]/46,XY [7]
47 PD M6 0 47,XY,+8[12]/46,XY [8]
47 Rel M1 4 46,XY,t(1;17)(q21;q23),inv(6)(p21q27),
t(9;13)(q21;q14)[5]/46,XY [16]
PD = Primary diagnosis; Rel = relapse; n.d. = not done.
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Table 4. FLT3-LM status in paired samples at presentation and relapse (n = 49)
FLT3 status at diagnosis
1 2 3 4 5 0 0 0 0 1 1 1 2 2 3 1 2 4 5
FLT3 status at relapse
1 2 3 4 5 1 2 3 4 2 3 4 3 4 4 0 0 2 2
Patients
– 6 2 3 1 1 1 1 1 1 3 5 9 5 3 3 1 1 1
Total patients
constant: n = 12 progression: n = 30 regression: n = 6
Table 5. Karyotype in paired samples at presentation and at relapses in patients with FLT3-LM
Diagnosis Relapse Total (n = 44)
Constant (n = 26) normal karyotype normal karyotype 23
aberrant karyotype same aberrant karyotype 4
Progression (n = 9) normal karyotype aberrant karyotype 5
aberrant karyotype same aberrant karyotype with additional aberrations 4
Regression (n = 6) aberrant karyotype normal karyotype 3
aberrant karyotype less aberrant karyotype 3
Change (n = 3) aberrant karyotyp regression + progression 3
Comparison of FLT3 Status and Karyotype
Karyotype at diagnosis and relapse was available in 44
paired samples. Most of the cases (n = 23) had a normal
karyotype at both time points and 4 cases had equal aber-
rant karyotypes of the prognostically intermediate karyo-
type group. Thus 27/44 cases (61.4%) had stable karyo-
types. However, of these 27 cases with stable karyotype 18
had a progression of the FLT3-LM. Five cases with nor-
mal karyotype had a chromosomal aberration at relapse.
In addition, 5 cases with aberrations had additional aber-
rations at relapse. All these aberrations were of the prog-
nostically intermediate group as is characteristic for cases
with FLT3-LM; thus there was no change with regard to
the cytogenetically defined risk group but only gains of a
so-called additional chromosomal aberration in the sense
of progression. Five of the 10 cases with karyotype pro-
gression in parallel showed progression of the FLT3 sta-
tus. In 6 cases a karyotype regression was detected, 3 of
these had a regression and a progression in combination.
One (ID 43) also revealed regression of FLT3-LM; how-
ever, 5 of these cases revealed a progression of the FLT3-
LM. Thus cytogenetic regression can be replaced by a
molecular progression. Four cases (ID 5, 30, 46, 47) had
both a cytogenetic as well as a molecular regression.
Evaluation of FLT3-LM as Follow-Up Marker Using
Conventional PCR
The sensitivity as estimated by the limited dilution
series of FLT3-LM-positive patients’ RNA or DNA from
the time of diagnosis in samples negative for the mutation
was dependent on the strength of the initial mutation sta-
tus and was between 1:100 and 1:1,000 (fig. 2). The course
of the disease could be followed according to the wild-
type/mutation ratio of the amplification product.
In total 174 bone marrow samples of 45 patients were
analyzed during or after therapy. The median sample
number per patient was 4 and the median follow-up time
of sampling was 12 months.
In 6 cases it was possible to detect FLT3-LM positivity
after previous PCR negativity 1–3 months before cyto-
morphological relapse. In additional 4 cases a pending
relapse was detectable due to persistent PCR positivity of
the FLT3-LM (examples are depicted in fig. 3).
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Fig. 2. Limited dilution assays of FLT-LM-positive DNA of patients
with different status at diagnosis into FLT3-LM-negative DNA
showing the detection limits of FLT3-LM by conventional PCR.
FISH and PCR
In some cases it was possible to perform FISH analysis
or PCR using a second marker in parallel to FLT3-LM
PCR. For 11 patients with chromosome aberrations at
diagnosis a FISH marker was available for follow-up.
Four patients with reciprocal translocations could be ana-
lyzed with respective colocalization probes [AML1-ETO
(n = 2), PML-RARA and CBFB-MYH11]. Four cases had
a trisomy 8 that was followed by a centromere 8 probe.
One had a 5q- and 2 a 7q- that were analyzed with probes
from the respective deletion region. In the 4 cases with
AML1-ETO, PML-RARA, and CBFB-MYH11 fusion
Fig. 3. Follow-up analyses in some exemplary patients showing the possibility of controlling therapy response and of
detecting relapses early. Rel = Relapse; CR = complete remission; BMT = bone marrow transplantation.
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gene-specific PCR and FISH were done in parallel to
FLT3-PCR. In each of these cases fusion gene-specific
PCR was the most sensitive method. In 6 cases (1 !
AML1-ETO, 1 ! PML-RARA, 2 ! +8, 1 ! 7q-, 1 ! 5q-)
FISH and FLT3 revealed comparable results during fol-
low-up. One case with AML1-ETO and the one with
CBFB-MYH11 and low FLT3-LM at diagnosis lost their
FLT3-LM at relapse. Two of the cases with trisomy 8, 1
with 7q- and the 1 with 5q-, lost these chromosomal aber-
rations at relapse but retained the FLT3-LM or even
revealed a progression of the FLT3-LM. Thus, for pa-
tients with fusion genes, fusion gene-specific PCR or even
FISH clearly are superior to FLT3-PCR. However, in
cases with other aberrations like trisomy 8, 5q- or 7q-
FLT3-LM PCR seems to be the more reliable follow-up
marker.
Discussion
FLT3-LM is the most frequent genetic marker in
AML. It is most commonly found in the intermediate risk
group, a subgroup of AML where PCR markers for follow-
up controls have been missing so far. Therefore, it was
suggested that an FLT3-LM should be used as a follow-up
marker [8]. However, many studies reported on the insta-
bility of this marker during the course of the disease [42–
45]. Here we performed a comprehensive analysis regard-
ing the applicability of the FLT3-LM as a follow-up
marker.
We and others have previously shown that the amount
of FLT3-LM in comparison to the wild-type allele is het-
erogeneous [7, 8]. In the present study in 17% of the
patients at diagnosis and in 84% at relapse partial or com-
plete loss of the wild-type allele was found. Although the
clinical significance of FLT3-LM per se is still discussed
controversely the loss of the wild-type allele was reported
to be clearly associated with a worse outcome [7, 46].
These patients have a higher white blood cell count, a
higher percentage of bone marrow blasts, and a shorter
overall and disease-free survival [7, 16, 46]. The loss of
WT-FLT3 is of interest with respect to functional aspects.
As a mutant FLT3 in a mutant/wild-type heterodimer can
trans-phosphorylate the wild-type chain [47]; it implies
that a mutant homodimer has some gain of function more
than simply activating the kinase. Alternatively, forma-
tion of the homodimer may reflect an underlying mecha-
nism of genetic instability that has other unknown ge-
nomic consequences that may, in turn, influence clinical
outcome.
Different incidences of the patients with loss of the
wild type were described in different studies. Whereas
Whitman et al. [46] found in 8/23 (35%) of their patients a
level of mutant greater than the wild-type allele (WT),
Fröhling et al. [17] found it in only 1/71 (1.4%). To some
extent, this may reflect differences in the cut-off value for
loss of wt allele and stresses the need for a truly quantita-
tive assessment of the FLT3 mutation status even at diag-
nosis. We found a higher FLT3-LM ratio in comparison
to the wt in 11% at diagnosis, in 32% at relapse, and com-
plete loss of the WT-FLT3 in 6% at diagnosis and 52% at
relapse. Thus a loss of the WT-FLT3 is not only associated
with a worse prognosis but, in addition, accumulates dur-
ing the course of the disease and thus seems to be a marker
for more progressed disease.
Several studies have been published investigating
FLT3 mutations in paired presentation and relapse sam-
ples [8, 42–44, 48]. In some of these studies 7–15% of all
AML revealed a gain of the FLT3-LM at relapse [43, 44].
Like in the study presented many of the patients lost their
wt at relapse. This accumulation of the FLT3-LM implies
a role of FLT3-LM in leukaemia progression and onset of
relapse.
Taking the results of these previous studies together
with those of the study presented only 88% of the ana-
lyzed patients maintained the same FLT3 status (FLT3-
LM positive or negative) at both time points. Consequent-
ly, as was suggested previously [45] the FLT3-LM should
be regarded with caution with respect to its usefulness as a
follow-up marker. Patients that were positive for an
FLT3-LM at presentation often showed an increased mu-
tant level at relapse, usually with evidence of the loss of
wild-type alleles. Where more than one mutation had
been detected at presentation, usually only one was domi-
nant at relapse [8, 43, 44]. Thus accumulation in the sense
of progression seems to be the most common direction of
the instability of the FLT3-LM and does not interfere
with the applicability for MRD diagnostics. However, in
some studies a significant proportion of patients either
gained (8.3%) or lost (4%) an FLT3-LM at relapse, and
some patients have been reported with a loss of the pre-
sentation LM and a gain of a completely new one at
relapse [42–44]. These data imply that FLT3-LM are sec-
ondary events, arising in an already transformed clone,
which induce the outgrowth of a subclone as a result of an
additional proliferative advantage conferred by the
FLT3-LM. Further support for the secondary etiology of
the FLT3-LM is given by those cases that carry the FLT3-
LM in only a subset of their leukaemic cells (status 1
mutation in the study presented). In our study all cases
76 Acta Haematol 2004;112:68–78 Schnittger/Schoch/Kern/Hiddemann/
Haferlach
with a loss of the FLT3-LM at relapse revealed only a low
FLT3-LM/wt ratio at diagnosis. One of the cases had a
t(8;21) and one an inv(16) which are subtypes with a rare
incidence of FLT3-LM. Also in these cases there seems to
be only an FLT3-LM-positive subclone at diagnosis
which got lost at relapse. Also these cases had cytogeneti-
cally normal clones at diagnosis and not at relapse. Thus
in cases with only a low mutation ratio at diagnosis the
results of the follow-up analysis should be regarded with
special care.
Detailed cytomorphological, cytogenetic, and immu-
nophenotypic analysis of our cases with a loss of the
FLT3-LM at relapse revealed a shift of the FAB type and
immunophenotype in 2 cases and a complete change of
the karyotype in another 2 cases, suggesting that these
AML might be secondary AML instead of relapses. Tak-
ing together our data and data published in the literature
(table 2), only 4% have a loss of the FLT3-LM. This would
be the subgroup that would escape early detection of
relapse. However, from our experience this is in the same
range as other leukaemias (for example, those followed up
with AML1-ETO or CBFB-MYH11) ‘relapse’ with a dif-
ferent AML. In all of these cases an impending relapse
cannot be detected with molecular methods. In addition,
therapy response in the early course of the disease can also
be applied in these 4% of cases.
For individual patients it was possible to apply differ-
ent methods of follow-up controls in parallel. It was
shown that in patients with fusion genes, fusion gene-spe-
cific PCR was clearly superior to FLT3-PCR because it is
quantitative instead of semiquantitative and more sensi-
tive. Even the fusion gene-specific FISH analysis was
more sensitive in these cases, because all these cases had a
very low FLT3-LM status at diagnosis. In contrast, in
cases with other aberrations like trisomy 8, 5q- or 7q-
FLT3-LM was more reliable than FISH specific for the
respective chromosome aberrations, because all these
chromosome aberrations were unstable at relapse and
FLT3-PCR although being not highly sensitive with a sen-
sitivity of 1:1,000 is more sensitive than FISH.
To make the FLT3-LM assessment truly semiquantita-
tive, we suggest that GeneScan analysis should be used at
diagnosis for better prognostication [7]. During follow-up
this method would also improve the estimation of the
reduction of the leukemic cells in comparison to standard
PCR and gel electrophoresis. It could be shown that real-
time quantification with patient-specific primers for indi-
vidual FLT3-LM is applicable and highly specific and
sensitive. Thus in the future a highly sensitive and quanti-
tative PCR may still improve the use of FLT3-LM as a
follow-up marker. However, this approach is time con-
suming and expensive and for prospective assessment of
the FLT3-LM in clinical studies it does not seem to be
feasible for most of the diagnostic labs.
As FLT3-LM characterizes an unfavourable subset of
the intermediate group with an increased risk for relapse
it is of high importance to monitor especially this group.
With the present study it could be shown that FLT3-LM
indeed is a reliable marker to assess therapy response and
it was even possible to detect relapse early up to 3 months
before a clinical relapse. In 94% of cases with FLT3-LM
at diagnosis it is also present at relapse. However, the
amount of the mutation in relation to the wild-type allele
is increasing in 63% of the cases. It seems to be a common
signature of the FLT-LM that the status is increasing in
the course of unfavourable disease.
Although the applicability of FLT3-LM as marker for
follow-up controls was regarded quite critically [43, 45]
the results of the presented study are encouraging. This
study using conventional qualitative PCR shows that
FLT3 is a reliable marker for follow-up controls in most of
the patients carrying an FLT3-LM at diagnosis.
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